Agenus

Agenus is now in the closing stretch of its multidecade effort to bring a drug to market. With the FDA set to decide whether to approve PD-1 drug balstilimab in December, Agenus has published the phase 2 data it hopes will secure authorization in cervical cancer.

Agenus, an immuno-oncology company based out of Lexington, Mass., has purchased a 120-acre plot of land near Genentech's manufacturing facility in Vacaville, Cali.

BMS inked a collaboration agreement with Exscientia that can leverage AI to speed the discovery of drug candidates in therapeutic areas, including oncology and immunology.

Under the terms of the agreement, Bristol Myers Squibb will take over complete responsibility for the development and commercialization of AGEN1777 and any related products globally.

Bristol Myers Squibb, looking to the future beyond Opdivo, has penned a major biobucks pact for two early-stage assets out of small biotech Agenus.

Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a broad pipeline which includes checkpoint antibodies, cell therapies, adjuvants, and vaccines designed to activate immune response to cancers and infections, today announced the expansion of a Phase 2 trial into colon cancer based on a new objective clinical response in a colorectal cancer patient in addition to a significant tumor reduction of 27% and biomarker reduction observed i